mk 0663 has been researched along with Osteoarthritis in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (62.96) | 29.6817 |
| 2010's | 17 (31.48) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YC; Chen, WF; Hsieh, SP; Hsuan Jean, Y; Lee, CH; Lee, HP; Lin, YY; Sung, CS; Tang, CC; Wen, ZH | 1 |
| Abdelkhalek, AA; Elkasabgy, NA; Salama, AH | 1 |
| Chen, G; He, J; Ji, C; Jiang, H; Liang, T; Liu, B; Luo, Z; Shao, Y | 1 |
| Davydkin, IL; Zolotovskaia, IA | 1 |
| Chen, WJ; Gates, DF; Lin, HY; Moore, RA; Peloso, PM; Popmihajlov, Z; Straus, WL | 1 |
| Huang, WN; Tso, TK | 1 |
| Feng, X; Mei, H; Tian, M; Zhang, W | 1 |
| Chiou, JY; Huang, YK; Peijer Hsieh, J; Peng, YS; Ting, HF; Wang, YH; Wei, JC; Xue, YH | 1 |
| Gahn, J; Han, B; Happich, M; Myers, J; Paget, MA; Price, K; Wielage, RC | 1 |
| Arunkumar, P; Indulekha, S; Srivastava, R; Vijayalakshmi, S | 2 |
| Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG | 1 |
| Caralli, ME; De Barrio Fernández, M; Pelta Fernández, R; Rojas Pérez-Ezquerra, P; Seoane Rodríguez, M | 1 |
| Cannon, CP; Cryer, B; Curtis, SP; Jensen, DM; Kaur, A; Laine, L; Langman, M | 1 |
| Davies, NM; Remsberg, CM; Reynolds, JK; Takemoto, JK; Vega-Villa, KR | 1 |
| Cannon, CP; Connors, LG; Curtis, SP; Goldkind, L; Laine, L; Yanqiong, Z | 1 |
| Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C | 1 |
| Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Swergold, G; Wang, H; Weir, MR | 1 |
| Croom, KF; Siddiqui, MA | 1 |
| Chen, MH; Chen, WJ; Cheng, TT; Gammaitoni, AR; Lac, C; Lee, CS; Lei, V; Lin, HY; Smugar, SS; Wang, JH | 1 |
| Alekseeva, LI | 1 |
| Bingham, CO; Gammaitoni, A; Peloso, PM; Smugar, SS; Wang, H | 1 |
| Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT | 1 |
| Adami, S; Gatti, D | 1 |
| Bowen, B; Callegari, P; Evans, J; Harper, S; Hunt, RH; James, C; Quan, H; Rashid, F; Yu, C | 1 |
| Capone, ML; Patrignani, P; Tacconelli, S | 1 |
| Hunsche, E; Mavros, P; Querol, J; Ramos-Remus, CR; Suarez, R | 1 |
| Crespi, S; Hunsche, E; Moore, A; Pellissier, J; Phillips, C | 1 |
| Leclercq, P; Malaise, MG | 1 |
| Bolognese, JA; Curtis, S; Krupa, D; Watson, DJ; Yu, C | 1 |
| Aversano, ML; Boice, JA; Ko, A; Murphy, FT; Reicin, AS; Sheldon, EA; Wiesenhutter, CW; Wittmer, BA | 1 |
| Hochberg, MC | 1 |
| Carracedo-Martínez, E | 1 |
| Krüger, K | 2 |
| Choi, YS; Kim, JA; Kim, SH | 1 |
| Bockow, B; Compton, A; Curtis, SP; Fisher, C; Ko, AT; Olaleye, J; Reicin, AS | 1 |
| Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L | 1 |
| Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM | 1 |
| Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME | 1 |
| Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS | 1 |
| Bolognese, JA; Cavanaugh, PF; Curtis, SP; Ko, AT; Reicin, AS | 1 |
| Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L | 1 |
| Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B | 1 |
| Einecke, D | 2 |
| Berrocal, A; Boice, JA; Cichanowitz, N; Fidelholtz, JL; Ko, A; Littlejohn, TW; Miranda, P; Puopolo, A; Reicin, AS | 1 |
| Baraf, HS | 1 |
| Bjarnason, NH; Gøtzsche, PC | 1 |
| Klotz, U; Shi, S | 1 |
| Derry, S; McQuay, HJ; Moore, OA; Moore, RA | 1 |
15 review(s) available for mk 0663 and Osteoarthritis
| Article | Year |
|---|---|
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Naproxen; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones | 2018 |
The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis.
Topics: Acetaminophen; Administration, Oral; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Drug Evaluation; Duloxetine Hydrochloride; Etoricoxib; Humans; Narcotics; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Thiophenes; Treatment Outcome | 2014 |
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2016 |
Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
Topics: Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Humans; Liver Failure; Osteoarthritis; Pain; Pyridines; Renal Insufficiency; Sulfones | 2008 |
Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
Topics: Arthritis, Gouty; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyridines; Spondylitis, Ankylosing; Sulfones | 2009 |
[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study pro
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2010 |
Coxibs: a significant therapeutic opportunity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Gastrointestinal Tract; Humans; Osteoarthritis; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones | 2010 |
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Topics: Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular System; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Low Back Pain; Membrane Proteins; Osteoarthritis; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfones | 2003 |
[Etoricoxib (Arcoxia)].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cyclooxygenase 2; Etoricoxib; Humans; Isoenzymes; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfones | 2004 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones | 2005 |
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Thrombosis | 2006 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Osteoarthritis; Peptic Ulcer; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyridines; Sulfones | 2007 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
15 trial(s) available for mk 0663 and Osteoarthritis
| Article | Year |
|---|---|
Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial.
Topics: Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Ontario; Osteoarthritis; Pain; Pain Management; Pain Measurement; Pyridines; Quality of Life; Sulfones | 2016 |
Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Joints; Male; Osteoarthritis; Pain; Pain Measurement; Prospective Studies; Pyridines; Quality of Life; Sulfones; Treatment Outcome | 2018 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Odds Ratio; Osteoarthritis; Prospective Studies; Pyridines; Risk Factors; Sulfones; Treatment Outcome | 2008 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Hospitalization; Humans; Liver Diseases; Male; Middle Aged; Osteoarthritis; Pyridines; Risk Factors; Sulfones | 2009 |
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergencies; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Odds Ratio; Osteoarthritis; Pyridines; Safety; Sample Size; Sulfones; Thrombosis | 2009 |
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Osteoarthritis; Pyridines; Sulfones | 2009 |
Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial.
Topics: Aged; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Health Status; Humans; Male; Osteoarthritis; Pain; Patient Satisfaction; Prospective Studies; Pyridines; Quality of Life; Range of Motion, Articular; Recovery of Function; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Treatment Failure; Treatment Outcome | 2010 |
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Treatment Outcome | 2011 |
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ulcer; Etoricoxib; Female; Gastrointestinal Hemorrhage; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Occult Blood; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyridines; Stomach Ulcer; Sulfones | 2003 |
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis; Pyridines; Sulfones | 2005 |
Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
Topics: Administration, Oral; Aged; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis; Pyridines; Sulfones; Treatment Outcome | 2005 |
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Pyridines; Severity of Illness Index; Sulfonamides; Sulfones; Thrombosis; Treatment Outcome | 2007 |
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Time Factors; Treatment Outcome | 2007 |
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pyridines; Sulfones; Treatment Outcome; Withholding Treatment | 2007 |
A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis; Pain Measurement; Placebos; Pyridines; Statistics as Topic; Sulfones; Treatment Outcome | 2007 |
24 other study(ies) available for mk 0663 and Osteoarthritis
| Article | Year |
|---|---|
The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF-β1 and NGF expressions in chondrocytes.
Topics: Animals; Chondrocytes; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Etoricoxib; Nerve Growth Factor; Nociception; Osteoarthritis; Rats; Transforming Growth Factor beta1 | 2020 |
Etoricoxib-loaded bio-adhesive hybridized polylactic acid-based nanoparticles as an intra-articular injection for the treatment of osteoarthritis.
Topics: Adhesives; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Calcium; Cell Line; Cell Survival; Chitosan; Drug Liberation; Etoricoxib; Humans; Injections, Intra-Articular; Nanoparticles; Osteoarthritis; Polyesters; Polysorbates | 2020 |
Etoricoxib decreases subchondral bone mass and attenuates biomechanical properties at the early stage of osteoarthritis in a mouse model.
Topics: Animals; Biomechanical Phenomena; Bone Density; Disease Models, Animal; Etoricoxib; Knee Joint; Male; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Osteoarthritis; X-Ray Microtomography | 2020 |
[Cognitive-cytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Cytokines; Etoricoxib; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Meloxicam; Osteoarthritis; Prospective Studies; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Transforming Growth Factor beta1 | 2017 |
Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dementia; Diclofenac; Etoricoxib; Female; Humans; Incidence; Male; Middle Aged; Osteoarthritis; Proportional Hazards Models; Research Design; Retrospective Studies; Risk; Taiwan | 2018 |
[Non-selective NSAIDs and coxibs: what are myths, what are facts?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoricoxib; Humans; Long-Term Care; Osteoarthritis; Pain; Pain Management; Pyridines; Sulfones; Treatment Outcome | 2013 |
Synthesis, characterizations, in vitro and in vivo evaluation of Etoricoxib-loaded Poly (Caprolactone) microparticles--a potential Intra-articular drug delivery system for the treatment of Osteoarthritis.
Topics: Animals; Chemistry Techniques, Synthetic; Drug Carriers; Drug Liberation; Etoricoxib; Injections, Intra-Articular; Microspheres; Osteoarthritis; Polyesters; Pyridines; Rats; Sulfones; Synovial Fluid | 2016 |
Poly (caprolactone) microparticles and chitosan thermogels based injectable formulation of etoricoxib for the potential treatment of osteoarthritis.
Topics: Animals; Cell Line; Chitosan; Delayed-Action Preparations; Etoricoxib; Gels; Humans; Male; Mice; Osteoarthritis; Polyesters; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Sulfones | 2016 |
Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Drug Eruptions; Etoricoxib; Exanthema; Female; Humans; Middle Aged; Osteoarthritis; Patch Tests; Pyridines; Sulfones | 2016 |
Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance.
Topics: Cyclooxygenase 2 Inhibitors; Drug Approval; Etoricoxib; France; Humans; Insurance, Health, Reimbursement; Osteoarthritis; Pyridines; Sulfones | 2010 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diclofenac; Etoricoxib; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Osteoarthritis; Peptide Fragments; Prospective Studies; Pyridines; Retrospective Studies; Risk Factors; Sulfones; Thrombosis; Treatment Outcome | 2011 |
Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Low Back Pain; Male; Mexico; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pilot Projects; Pyridines; Quality of Life; Sulfones | 2004 |
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Middle Aged; Misoprostol; Models, Economic; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Quality-Adjusted Life Years; Risk; Sulfones; Time Factors; United Kingdom | 2004 |
[Rapidly acting and powerful antirheumatic drug now also approved in Germany. Arcoxia (etoricoxib, MSD)]].
Topics: Acute Disease; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Approval; Etoricoxib; Gout; Humans; Indomethacin; Osteoarthritis; Pain Measurement; Pyridines; Sulfones | 2004 |
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Method; Dyspepsia; Etoricoxib; Humans; Low Back Pain; Osteoarthritis; Patient Compliance; Protective Agents; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Spondylitis, Ankylosing; Sulfones | 2004 |
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Etoricoxib; Humans; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Sulfones; United Kingdom | 2005 |
Adverse effects of etoricoxib: other considerations.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoricoxib; Gastrointestinal Diseases; Humans; Osteoarthritis; Pyridines; Sulfones | 2005 |
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoarthritis; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Sulfones; Treatment Outcome | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones | 2006 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Germany; Humans; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Rheumatic Diseases; Risk Factors; Sulfones; United States | 2007 |
[Coronary risks with NSAID and coxibs. The end of hysteria].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause of Death; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis | 2006 |
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones | 2006 |
COX-2 inhibitor.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones | 2007 |
Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain; Pain Measurement; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sulfones | 2008 |